Ai Feedback
Exact(8)
Post-randomization measures at weeks 28 and 52 were tested for between-week and treatment effects.
There were no gender differences for any baseline measures or for most of the 19 functional outcome measures at weeks 4 and 16.
Participating adolescents with significant depressive symptomatology, aged 12 to 18 years, will complete assessment measures at Weeks 0, 12 and 24 of treatment.
Different single and composite measures at weeks 0, 6, 14 and 22, and their differences over time were taken into account for the model building.
This study differentiated active drug from placebo in clinical composite outcome measures at weeks 12 and 16 but failed to reach its primary endpoint at week 14.
In the acute phase, there was a statistically significant mean reduction (improvement) versus placebo on each MFI domain scale rating and BPI average pain measures at weeks 4, 8, and 12.
Similar(52)
CBZ treatment yielded significantly greater improvements on the three efficacy measures at week 8 through endpoint compared to placebo.
CBZ monotherapy produced significantly greater improvement on manic measures at week 2 through endpoint and CGI-S of depression at endpoint compared to placebo.
There were few significant differences in the impact of the three treatments on mean scores of quality-of-life measures at week 16.
Biomarker changes from baseline to week 4 were also correlated with clinical measures at week 14.
Table 2 summarises the effects of apremilast on additional efficacy measures at week 24.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com